Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. - Wikidata - wikimedia - TriplyDB

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

http://www.wikidata.org/entity/Q36267666

about

Current challenges and novel treatment strategies in double hit lymphomas MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.Role of MYC in B Cell Lymphomagenesis.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.Metadherin interference inhibits proliferation and enhances chemo-sensitivity to doxorubicin in diffuse large B cell lymphoma.Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.A Case of Advanced Primary Thyroid Double-Hit B Cell Lymphoma in Which Complete Remission has been Maintained After High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Performed During the Second Remission, with a Review BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis.Immunohistochemistry for myc predicts survival in colorectal cancer.Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.The histological classification of diffuse large B-cell lymphomas Blood and marrow transplant clinical trials network state of the Science Symposium 2014 Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma

P2860

Q26770385-4A9CACC9-36E8-4F84-9138-3D564AD7B4D8 Q26785379-0C50F77B-67C7-45A0-870F-E13B201DC36F Q26797469-0E0823FC-AC4F-4FC2-A3C3-9617EBE2F1D2 Q27304386-75BFDF65-501F-458C-8C1C-A7724B78E5F9 Q28067817-7C4FB61B-3441-4F1E-BE61-5D406454E95B Q28078869-AC41CB1A-3392-4C73-AE4C-BC19CB169A6A Q30240133-CE3D5359-E56C-4994-A1C4-D4F43A9ADB38 Q30275206-E966E48E-0585-4E35-BFFE-48259C412A30 Q33410380-DB8A6668-AC23-465A-AD06-CB66E9167508 Q33412553-53AACF47-C763-4D89-9FCF-07F39403A436 Q33438494-E4999071-0C33-47D4-9671-E944124195D8 Q33601156-C2601D39-7659-47DF-801C-A77B64E08204 Q33608499-86E762BC-3235-448F-A2BC-6F59432E094D Q33700531-219D94A4-11A0-4B96-B39A-03C107D714EF Q33702340-B7A2E281-9F8F-434E-A098-CFA5B61BC0A4 Q33729711-6341E8C6-0AC6-431A-8AA1-A5DA63325252 Q33809728-EB23A500-5E80-4F90-941E-758B45DCB44C Q33846801-381B4237-9D80-40D7-BF5C-F19C8A830FE5 Q33934326-6261212E-009F-4457-B202-494EB89A1014 Q34000188-FA6E9EBD-3BE6-4C6F-8307-8A0EC83685CB Q34167090-09247FD9-7D30-4396-B8FC-1EEFC897583F Q34293007-32475846-BE77-42FC-A1BD-40C5D9E35BB2 Q34316137-2D408CD3-1606-4C2D-9531-22434869DE30 Q34339662-005DF4C8-3C45-4FB8-B613-F1DC8A8700DA Q34640550-AB8FE374-14A3-4EA8-93EE-026A9A62391D Q34860750-9A52780D-85BA-4A74-B9CF-16EECBDE2A6D Q34882773-77EB41DE-2875-4FC4-945C-BCBC8EC1280C Q34918948-D02B7088-7DE5-4DE8-A49F-5E092D097F44 Q35030096-1EB4AF5D-E50B-47D1-A588-87A41AB02723 Q35051842-D8A35E19-3C56-41D1-9EEA-E33CB1BDE0C2 Q35087649-4A09CCBE-ABA0-4D47-8197-F018E126EBC4 Q35128216-2519D765-4078-4EA1-8576-2EC4E3CBC890 Q35150618-D01E1CC6-E1CA-4EA5-A3FB-4E00C6DF5C4E Q35157633-6B1C08D8-97A6-40E4-8735-AB85CC5D53EA Q35180822-61AD4258-0148-45AB-873D-03CFE3A975F4 Q35218051-E1CD8D8E-566A-404E-993B-E72EC626B058 Q35591760-7002FFDE-89ED-42A5-9681-81DB56C3DE37 Q35740025-1EF49A0A-9D07-4849-8C54-70FEFA64F3C7 Q35755485-72B266D1-EA22-4A40-9FA6-2694E5CE2B4D Q35797583-D32F73FA-90C2-4544-BCED-85A172F75EF0

P2860

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

http://www.wikidata.org/entity/Q36267666

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Concurrent expression of MYC a ...... , vincristine, and prednisone.

@ast

Concurrent expression of MYC a ...... , vincristine, and prednisone.

@en

type

label

Concurrent expression of MYC a ...... , vincristine, and prednisone.

@ast

Concurrent expression of MYC a ...... , vincristine, and prednisone.

@en

prefLabel

Concurrent expression of MYC a ...... , vincristine, and prednisone.

@ast

Concurrent expression of MYC a ...... , vincristine, and prednisone.

@en

P1433

Q36267666-D53ED3BC-BA46-4053-8B64-12AC4B760D4A

P1476

Q36267666-D1688E0A-353B-498B-B238-9B9ADA0BCF3E

P2093

Q36267666-10C5E0B7-7CD7-4B9D-878B-F2FBDE392966

Q36267666-1BB5B926-0734-489E-B183-7D39639CFB11

Q36267666-1C490FB6-BED4-4767-A5F0-B5BEDFDFC332

Q36267666-1FFB9D1F-A3FD-4456-B3C6-8349F10D8C38

Q36267666-32053A5F-BFD3-47E7-95E3-94B6BDAB4CE3

Q36267666-3D0890CE-8909-4115-B7B4-DCA6BB005323

Q36267666-443C9C6C-09E8-4635-BB6F-9012D3D17C49

Q36267666-5978DB9E-E0A1-48F1-B469-152B8C06A6C9

Q36267666-610883C2-F13B-419D-9690-9046D14C73D6

Q36267666-6E5ECD69-1FCE-47B1-927F-91E96052B375

P2860

Q36267666-00A54602-007A-475D-83FC-897342D4BFF4

Q36267666-02B28FE5-3C88-4675-9A41-DA7DA85D50DE

Q36267666-0876C7DF-564B-406C-BF30-27003CF61D9A

Q36267666-0B427C43-0CF2-439C-9249-8CCAA6775237

Q36267666-0F22FF8A-B69C-4673-A2C0-F81E695F0556

Q36267666-183CC7D5-D3A4-4F8A-ABEE-9621A0FE3FBA

Q36267666-215113A6-CBCC-4A46-A98F-2051F32CEBC5

Q36267666-303C9628-325C-44C4-84F8-565AD79EE129

Q36267666-3D3316DE-7238-402A-B7F6-545C4A9E5C7F

Q36267666-3D39D5DD-D3CA-44FC-A996-FBBCC33D3944

P304

Q36267666-83A018D3-952E-4E41-96F7-FDF7F156CDCC

P31

Q36267666-C8948A94-221E-4303-A10F-53A90DE72BD8

P356

Q36267666-C3655CED-3D41-4B64-A60E-41C2B279B090

P407

Q36267666-8C6FEE8A-8C0E-47D4-AA4E-C7C63B7DF608

P433

Q36267666-B85782A2-07FD-45FD-9728-D7C2D1F490D7

P478

Q36267666-822E199F-96D3-4052-A668-EC2B11936596

P50

Q36267666-02B960F4-776E-460F-91DC-F975CD3C5CE2

Q36267666-2838CA28-AC69-4E54-9C84-2469F6BFBCBB

Q36267666-2FD2DE10-8ADD-484E-B574-466E4F8ECB9E

Q36267666-4F459454-2482-44D1-91D4-B2D6DDFCF06E

Q36267666-612F3A1D-2F54-4147-A53D-90685727B533

Q36267666-B8774D3A-C535-4DB4-AD81-FEC7C8C16719

Q36267666-F385C2C5-04E3-41EC-BEA6-6F344DE3F10D

P577

Q36267666-284DAC35-6469-45CD-BC64-39D31A808D97

P5875

Q36267666-3FDC2654-2210-40D3-90E4-155FA5E007DC

P698

Q36267666-961485C1-F6D2-4908-BB98-2D43827893E5

P932

Q36267666-CC8FF616-B718-499D-B03D-3B2DEA88516C

P356

JCO.2011.41.0985

P1433

Journal of Clinical Oncology

P1476

Concurrent expression of MYC a ...... , vincristine, and prednisone.

@en

P2093

Andreas Rosenwald

http://www.w3.org/2001/XMLSchema#string

Carlo Valentino

http://www.w3.org/2001/XMLSchema#string

Christian Steidl

http://www.w3.org/2001/XMLSchema#string

Christina Holcroft

http://www.w3.org/2001/XMLSchema#string

David W Scott

http://www.w3.org/2001/XMLSchema#string

Georg Lenz

http://www.w3.org/2001/XMLSchema#string

George Wright

http://www.w3.org/2001/XMLSchema#string

German Ott

http://www.w3.org/2001/XMLSchema#string

Graham W Slack

http://www.w3.org/2001/XMLSchema#string

James R Cook

http://www.w3.org/2001/XMLSchema#string

P2860

Widespread microRNA repression by Myc contributes to tumorigenesis

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

Aggressive lymphomas

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

Stromal gene signatures in large-B-cell lymphomas

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

P304

3452-3459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.41.0985

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Joseph M Connors

Randy D Gascoyne

Dennis D Weisenburger

P577

2012-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230592881

http://www.w3.org/2001/XMLSchema#string

P698

22851565

http://www.w3.org/2001/XMLSchema#string

P932

3454768

http://www.w3.org/2001/XMLSchema#string